Monday, May 8, 2017

India Globalization Capital, Inc. (NYSE: IGC) Positioned to Lead in Phytocannabinoid Pharmaceuticals

A study recently highlighted by the American Epilepsy Society (AES) at its 70th annual meeting focused on the potential of cannabidiol (CBD), a derivative of the cannabis plant, as a promising treatment for reducing both the frequency and severity of seizures in children with drug resistant epilepsies ( According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.

Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad range of beneficial therapeutic uses in humans and animals including pain mitigation, epileptic seizures and wasting disease eating disorders (cachexia). Animal studies have also shown promise for CBD’s anticonvulsant efficacy in multiple species (

As referenced in a recent article (, multiple companies compete in the $65 billion diverse pet product market, with about $15 billion spent on veterinary care annually in the United States. Seizures afflict about five percent of the 90 million dogs in the U.S. and a little over two percent of the 94 million felines. The most commonly used drugs to treat pet seizures include a lifetime regimen of phenobarbital, potassium bromide, and diazepam. India Globalization Capital, Inc. (NYSE MKT: IGC) is changing the paradigm of seizure treatments for dogs and cats based on its novel patent pending therapy using cannabinoid extracts.

India Globalization Capital is actually building a broad portfolio of multiple intellectual properties around the utilization of phytocannabinoid-based therapies in both animals and humans. The company is at the forefront of the combined use of cannabis-based extracts with other medications to reduce side effects and to increase bioavailability and absorption (phytocannabinoid-based combination therapy).

IGC has developed a pipeline of patent pending cannabinoid-based drugs targeting large market disorders such as therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic compounds are scheduled for pre-clinical trials this year. With a team of experts encompassing patent law, clinical trials and regulatory procedures, IGC is positioned to become a leader in specialty pharmaceuticals and offers an interesting opportunity to profit from this exciting new market.

For more information, visit the company’s website at

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at

The Quality Stocks Daily Blog

The Quality Stocks Daily Videos

The Quality Stocks “Ones to Watch”

Please see disclaimer on the QualityStocks website:

No comments: